EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection

Shuang Xiao, Qianwen Fu, Youhan Miao, Manna Zhao, Shengwei Lu, Jie Xu, Weifeng Zhao

Frontiers in Microbiology · 17.08.2023 · 14

DOI: 10.3389/fmicb.2023.1198926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 17.08.2023. Verfasst von Shuang Xiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To examine the clinical efficacy, safety, and resistance of Ceftazidime-Avibactam (CAZ-AVI) in patients with Carbapenem-resistant Gram-negative bacilli (CR-GNB) infections.

Methods

We retrospectively analyzed relevant data of CR-GNB infected patients receiving CAZ-AVI treatment, analyzed relevant factors affecting drug efficacy, and compared the efficacy and safety with patients receiving Polymyxin B treatment.

Results

A total of 139 patients were included. Agranulocytosis, septic shock, SOFA score, and CAZ-AVI treatment course were independent risk factors affecting the prognosis of patients with CR-GNB infection treated with CAZ-AVI while prolonging the treatment course of CAZ-AVI was the only protective factor for bacterial clearance. The fundamental indicators showed no statistically significant differences between CAZ-AVI and Polymyxin B treatment groups. At the same time, the proportion of patients treated with monotherapy was significantly higher in the CAZ-AVI group than in the Polymyxin B group (37.2% vs. 8.9%, p < 0.05), the 30-day mortality rate of the CAZ-AVI treatment group (27.7% vs. 46.7%, p = 0.027) was lower than that of the Polymyxin B treatment group. The 30-day clinical cure rate (59.6% vs. 40% p = 0.030) and 14-day microbiological clearance rate (42.6% vs. 24.4%, p = 0.038) were significantly higher in the CAZ-AVI than in the Polymyxin B treatment group. Eighty nine patients were monitored for CAZ-AVI resistance, and the total resistance rate was 14.6% (13/89). The resistance rates of Carbapenem-resistant Klebsiella pneumoniae (CRKP) and Carbapenem-resistant Pseudomonas aeruginosa (CRPA) to CAZ-AVI were 13.5 and 15.4%, respectively.

Conclusion

CAZ-AVI has shown high clinical efficacy and bacterial clearance in treating CR-GNB infections. Compared with Polymyxin B, CAZ-AVI significantly improved the outcome of mechanical ventilation in patients with septic shock, agranulocytosis, Intensive Care Unit (ICU) patients, bloodstream infection, and patients with SOFA score > 6, and had a lower incidence of adverse events. We monitored the emergence of CAZ-AVI resistance and should strengthen the monitoring of drug susceptibility in clinical practice and the rational selection of antibiotic regimens to delay the onset of resistance.

Schlagwörter

Stichwörter der Autor:innen

Polymyxin Bcarbapenem-resistant gram-negative bacilliceftazidime-avibactamclinical efficacydrug resistance

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Critical Care Medicine, The First People's Hospital of Tonglu, Hangzhou, China.
  • Department of Infectious Diseases, The Third Affiliated Hospital of Nantong University, Nantong, China.
  • Center of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.

Zitieren

APA

Xiao, S., Fu, Q., Miao, Y., Zhao, M., Lu, S., Xu, J., & Zhao, W. (2023). Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1198926

Vancouver

Xiao S, Fu Q, Miao Y, Zhao M, Lu S, Xu J, et al. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1198926

BibTeX
@article{Xiao2023,
  author = {Xiao, Shuang and Fu, Qianwen and Miao, Youhan and Zhao, Manna and Lu, Shengwei and Xu, Jie and Zhao, Weifeng},
  title = {Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection},
  journal = {Frontiers in Microbiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fmicb.2023.1198926}
}
Kostenlos starten →